Role of the DREAM complex in the lung tumor suppression
DREAM 复合物在抑制肺部肿瘤中的作用
基本信息
- 批准号:10575588
- 负责人:
- 金额:$ 21.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-03 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinoma CellAllelesAnimalsBindingBreedingBypassCDKN2A geneCRISPR/Cas technologyCancer EtiologyCell AgingCell CycleCell Cycle ArrestCell Cycle ProgressionCell ProliferationCell SurvivalCellsCessation of lifeChronicClinical DataCommunitiesComplexCopy Number PolymorphismDNA DamageDNA RepairDNA Repair GeneData AnalysesDetectionDevelopmentDiagnosticDiseaseEarly DiagnosisEnvironmental Risk FactorEpithelial Cell ProliferationEpithelial CellsExperimental ModelsExposure toFutureGene ExpressionGene Expression RegulationGene TargetingGenesGeneticGenetic TranscriptionGenetically Engineered MouseGenomeGenotoxic StressGrowthGrowth FactorHeterozygoteHistologicHumanHuman Cell LineImmuneIn VitroInflammatoryInvestigationKRAS2 geneKnock-inKnowledgeLesionLungLung AdenocarcinomaLung NeoplasmsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMeasurementMediatingMessenger RNAModelingMolecularMouse Cell LineMusMutant Strains MiceMutateMutationNon-Small-Cell Lung CarcinomaOncogenicOutcomePathogenesisPathway interactionsPhenotypePhosphorylationPhosphotransferasesPhysiologicalPlayPreventionPrevention strategyProliferatingProliferation MarkerProtein FamilyProtein KinaseProteinsRadiationRadiation induced damageRadonRecording of previous eventsRepressionRepressor ProteinsResearchRetinoblastomaRetinoblastoma ProteinRisk FactorsRoleSerineSignal TransductionSmokerSquamous cell carcinomaStagingTP53 geneTestingThe Cancer Genome AtlasTobacco smokeTobacco smoking behaviorTranscription RepressorTumor SuppressionTumor Suppressor Proteinsairway epitheliumcancer initiationcdc Genescell injurydetection of nutrientdriver mutationgenome editinggenotoxicityhigh rewardhigh riskirradiationlung carcinogenesislung histologylung tumorigenesismRNA Expressionmouse modelmutantneoplasticnovelnovel strategiespremalignantpreventpromoterprotein expressionrecruitrepairedresponsesenescencesmall cell lung carcinomasurvival outcometargeted treatmenttobacco exposuretumortumor progressiontumorigenesis
项目摘要
ABSTRACT
Lung cancer is the major cause of cancer deaths in the U.S. and worldwide. The most common types of lung
cancer are non-small cell lung carcinoma (NSCLC, 84%) and small cell lung carcinoma (SCLC, 13%). NSCLC
includes two major histological subtypes, adenocarcinoma (AC), and squamous cell carcinoma (SCC). All
subtypes of lung cancer are thought to arise from airway epithelial cells damaged by genotoxic exposure, which
most commonly include tobacco smoke and radon radiation. These damaged cells frequently acquire early driver
mutations in the KRAS gene that could be also present in advanced lung cancers. However, even in the cases
with significant and chronic exposure (such as in heavy smokers), not all damaged cells give rise to cancer, and
the mechanisms that prevent the progression of early premalignant lesions to cancer are still not fully understood.
Studies using genetically engineered mouse models (GEMMs) highlighted the roles of cell cycle arrest and
senescence, mediated by retinoblastoma (Rb) family proteins and p53, in protection from lung tumorigenesis.
However, further research is required to better understand the barriers to lung carcinogenesis at the molecular
level, and to develop accurate models representing early stages of lung cancer pathogenesis.
Previously, we characterized a transcriptional repressor complex called DREAM that assembles in G0/G1
when Rb-like protein p130 recruits E2F4, DP1, and a stable core of five proteins including LIN9, LIN37, LIN52,
LIN54, and RBBP4. The DREAM binds to promoters and mediates the repression of >800 cell cycle genes,
including most genes required for DNA damage response and repair. Phosphorylation of serine-28 residue in
LIN52 by DYRK1A kinase is required for the DREAM assembly. DREAM-DYRK1A pathway could be relevant to
cancer because either inhibition of DYRK1A, or S28A-LIN52 mutation result in bypass of the oncogenic Ras-
induced senescence in the immortalized human and mouse cell lines. The KRAS gene is mutated in 15% - 30%
of NSCLC cases, and its driver role in lung cancer is strongly supported by encouraging NSCLC clinical data
using KRASG12C-targeted therapeutics. However, the pathophysiological significance of the DREAM disruption
in lung cancer is not known, and the mechanisms of senescence bypass in the cells lacking DREAM are not well
understood. Here, we test our hypothesis that DREAM complex contributes to tumor prevention by
suppressing DNA repair in the damaged cells during early stages of lung cancer pathogenesis.
Previously, the role of DREAM in lung cancer could not be directly investigated due to a lack of suitable mouse
models. To address this knowledge gap, we generated a DREAM-less mouse homozygous for S28A mutation
in the Lin52 gene, using CRISPR-Cas9 gene editing. We will use our novel Lin52S28A mouse model to investigate
the role of the DYRK1A-DREAM pathway during the early steps of lung cancer pathogenesis driven by genotoxic
stress or KrasG12C mutation.
摘要
肺癌是美国和世界范围内癌症死亡的主要原因。最常见的肺类型
癌症是非小细胞肺癌(NSCLC,84%)和小细胞肺癌(SCLC,13%)。非小细胞肺癌
包括两种主要的组织学亚型,腺癌(AC)和鳞癌(SCC)。全
肺癌的亚型被认为是由暴露于基因毒性环境中的呼吸道上皮细胞受损引起的,
最常见的包括烟草烟雾和氡辐射。这些受损的细胞经常获得早期驱动因素
KRAS基因的突变也可能存在于晚期肺癌中。然而,即使在这种情况下
长期大量接触(如重度吸烟者),并不是所有受损的细胞都会导致癌症,而且
阻止早期癌前病变进展为癌症的机制仍不完全清楚。
使用基因工程小鼠模型(GEMM)的研究强调了细胞周期停滞和
由视网膜母细胞瘤(RB)家族蛋白和P53介导的衰老在肺肿瘤发生中的保护作用。
然而,需要进一步的研究才能从分子上更好地了解肺癌发生的障碍。
水平,并开发代表肺癌发病机制早期阶段的准确模型。
在此之前,我们描述了一种称为DREAM的转录抑制复合体,它在G0/G1中组装
当Rb样蛋白p130招募E2F4、DP1和LIN9、LIN37、LIN52等5种蛋白质的稳定核心时,
LIN54和RBBP4。梦想与启动子结合,并介导对>;800细胞周期基因的抑制。
包括DNA损伤反应和修复所需的大多数基因。丝氨酸-28残基的磷酸化
DYRK1A激酶的LIN52是DREAM组装所必需的。Dream-DYRK1A通路可能与
癌症,因为抑制DYRK1A或S28A-LIN52突变导致绕过致癌的RAS-
在永生化的人和小鼠细胞系中诱导衰老。KRAS基因突变15%-30%
NSCLC病例中,其在肺癌中的驱动作用得到了令人鼓舞的NSCLC临床数据的有力支持
使用KRASG12C靶向疗法。然而,梦境破灭的病理生理学意义
在肺癌中的作用尚不清楚,缺乏DREAM的细胞的衰老旁路机制也不是很好
明白了。在这里,我们测试了我们的假设,即梦境复合体通过以下方式有助于肿瘤预防
在肺癌发病的早期阶段抑制受损细胞的DNA修复。
此前,由于缺乏合适的小鼠,不能直接研究DREAM在肺癌中的作用
模特们。为了解决这一知识差距,我们产生了一只S28A突变的无梦纯合子小鼠
在Lin52基因中,采用CRISPR-Cas9基因编辑。我们将使用我们的新型Lin52S28A小鼠模型来研究
DYRK1A-DREAM通路在基因毒性肺癌发病早期的作用
压力或KrasG12C突变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Larisa Litovchick其他文献
Larisa Litovchick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Larisa Litovchick', 18)}}的其他基金
Role of the DREAM Complex in Head and Neck Preneoplasia
DREAM 复合物在头颈部肿瘤前期的作用
- 批准号:
10189555 - 财政年份:2020
- 资助金额:
$ 21.77万 - 项目类别:
Role of the DREAM Complex in Head and Neck Preneoplasia
DREAM 复合物在头颈部肿瘤前期的作用
- 批准号:
10042333 - 财政年份:2020
- 资助金额:
$ 21.77万 - 项目类别:
DYRK1A signaling in control of cell growth, proliferation and DNA damage repair
DYRK1A 信号传导控制细胞生长、增殖和 DNA 损伤修复
- 批准号:
8963119 - 财政年份:2015
- 资助金额:
$ 21.77万 - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 21.77万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 21.77万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 21.77万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 21.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)